Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Legend Biotech Corporation - American Depositary Shares
(NQ:
LEGN
)
25.60
-0.15 (-0.58%)
Streaming Delayed Price
Updated: 11:31 AM EDT, Jul 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corporation - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
These stocks are gapping in today's session
↗
February 23, 2026
Via
Chartmill
These stocks are moving in today's pre-market session
↗
February 23, 2026
Via
Chartmill
HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model
↗
February 20, 2026
Baidu is transitioning from a search-driven advertising company into an AI infrastructure and enterprise cloud provider in China. HHLR’s exit comes as investors weigh whether this transformation will...
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
What to Expect from Legend Biotech's Earnings
↗
November 11, 2025
Via
Benzinga
How Do Investors Really Feel About Legend Biotech?
↗
September 22, 2025
Via
Benzinga
Legend Biotech Considering Second Listing Outside US: Report
↗
September 05, 2025
Via
Stocktwits
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
January 21, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares
↗
December 23, 2025
Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ pipeline.
Via
The Motley Fool
How Do Investors Really Feel About Legend Biotech?
↗
September 04, 2025
Via
Benzinga
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
↗
December 23, 2025
When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.
Via
The Motley Fool
Topics
Regulatory Compliance
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
December 06, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
November 13, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
November 12, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
November 03, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Inside the Fintech Platform Winning Over a New Generation of Investors in Asia
↗
October 31, 2025
Inside the Fintech Platform Winning Over a New Generation of Investors in Asia
Via
The Motley Fool
Topics
Derivatives
Regulatory Compliance
XP’s New Backer Sees Opportunity in Brazil’s Next Financial Chapter
↗
October 30, 2025
XP’s New Backer Sees Opportunity in Brazil’s Next Financial Chapter
Via
The Motley Fool
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
October 29, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
AMD To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Friday
↗
October 17, 2025
Via
Benzinga
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print
↗
October 14, 2025
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.
Via
Stocktwits
Topics
Government
World Trade
Expert Outlook: Legend Biotech Through The Eyes Of 6 Analysts
↗
October 09, 2025
Via
Benzinga
Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings
October 02, 2025
Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to...
Via
MarketMinute
Topics
Economy
Intellectual Property
Stocks
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
August 26, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
August 18, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
The Analyst Verdict: Legend Biotech In The Eyes Of 5 Experts
↗
August 12, 2025
Via
Benzinga
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
August 11, 2025
Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings....
Via
MarketMinute
Topics
Economy
Stocks
Legend Biotech Corp. (NASDAQ:LEGN) Reports Mixed Q2 2025 Earnings with Revenue Beat and EPS Miss Amid Strong CARVYKTI Sales
↗
August 11, 2025
Legend Biotech's Q2 2025 earnings show revenue beat at $255.1M, driven by strong CARVYKTI sales, but EPS missed at -$0.34. Stock rose 1.4% pre-market.
Via
Chartmill
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
August 11, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
